24/10/2019 – AB Science granted authorization to initiate phase 3 confirmatory study of masitinib in indolent systemic mastocytosis
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
24/10/2019 – AB Science granted authorization to initiate phase 3 confirmatory study of masitinib in indolent systemic mastocytosis